New clinical data surrounding this compound, specifically the high-dose formulation branded as ZPHC, indicate a significant impact on body mass decrease and linked metabolic conditions . Researchers posit that this innovative agonist , affecting both GLP-1 and GIP pathways , may offer a noteworthy improvement in the treatment of obesity and relate